Clanotech Receives Orphan Drug Designation in the EU
News Nov 04, 2014
Clanotech AB has announced that its anti-fibrotic and anti-angiogenic candidate drug CLT-28643 received orphan drug designation by the European Medicines Agency (EMA) for prevention of scarring post glaucoma filtration surgery. Karolinska Development has an 80 percent ownership in Clanotech.
Clanotech’s lead substance, an α5β1-integrin antagonist, has anti-angiogenic, anti-fibrotic and anti-inflammatory properties that are expected to benefit the wound healing processes following glaucoma surgery. The orphan drug designation will significantly shorten a future market approval process and reinforce market exclusivity for a launched product.
“We’re delighted by the positive response from the EMA, which underpins the great need for products that can improve the outcome of glaucoma surgery“, said Patrizia Caldirola, CEO, Clanotech.
“Therapies with potential for use in specialized care and orphan diseases are at the core of Karolinska Development’s investment strategy. The medical need for a safe and specific anti-fibrotic therapy in glaucoma surgery is substantial and the orphan drug designation will add significant value to this exciting pharmaceutical project”, said Bruno Lucidi, CEO, Karolinska Development.
Abzena Selects Sartorius Stedim Biotech to Equip its US Based Development and Manufacturing SitesNews
Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has selected Sartorius Stedim Biotech as its preferred equipment supplier in the U.S.READ MORE
Molecule Prevents Common Cold Virus from Hijacking Human CellsNews
Researchers have lab-tested a molecule that can combat the common cold virus by preventing it from hijacking human cells.READ MORE
Improving Pharmaceuticals: Catalyst Specifically Tuned to Integrate Fluorine AtomsNews
In the race to create more potent and stable medicines, scientists know that adding fluorine can improve drug molecules. However, there is only one fluorination reaction known to occur in nature which is performed by complex and highly specialized enzymes that are difficult to replicate. Now, scientists have developed a new, streamlined molecule that can do the work of enzymes but be designed and controlled minutely.READ MORE
Comments | 0 ADD COMMENT
World Congress on Bio-organic and Medicinal Chemistry
Nov 12 - Nov 13, 2018